Business Wire·Aug 13, 2026, 7:00 AM ET

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

Enrollment is ongoing in the Phase 2a/2b trial of YB-101, a potential first-in-class anti-TSHR antibody, for patients with Graves' disease with or without thyroid eye disease (TED).
Topline results from the Phase 2a portion of the trial are expected in the second half of 2027.
The Phase 2b portion is expected to commence in the first half of 2028.
The FDA granted Fast Track Designation for YB-101 in Graves' disease.
The company completed a reverse merger with VYNE Therapeutics 19; commenced trading on Nasdaq under the ticker symbol "YARW".
Previously announced private financings totaling $200 million were closed.
Cash and cash equivalents of $18.7 million as of June 30, 2026, plus $100 million received in July 2026, are expected to fund operations into 2028.
GenSci continues its Phase 1 multiple ascending dose study in TED in China, with data anticipated in the second half of 2027.
Research 19; development expenses totaled $4.9 million for the second quarter of 2026.
General 19; administrative expenses totaled $1.8 million for the second quarter of 2026.
Net loss totaled $6.5 million for the second quarter of 2026.
Subsequent to the merger, the company has approximately 28.6 million shares of common stock 19; common stock equivalents issued 19; outstanding.
The Phase 2a trial is a randomized, placebo-controlled proof-of-concept study involving 32 patients across four cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, 19; efficacy over 24 weeks.